Streetbeat News

Price Targets

DK

B of A Securities analyst Doug Leggate maintains a Neutral rating on Delek US Holdings (NYSE:DK) and raises the price target from $27.5 to $31.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 1:02 pm

LSXMK

Morgan Stanley analyst Benjamin Swinburne has maintained an Equal-Weight rating on Liberty SiriusXM Gr (NASDAQ:LSXMK) but lowered the price target from $36 to $24.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:02 pm

IOBT

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on IO Biotech (NASDAQ:IOBT) but has lowered the price target from $11 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:00 pm

DH

Morgan Stanley analyst Craig Hettenbach has maintained an Overweight rating on Definitive Healthcare (NASDAQ:DH), but lowered the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:59 pm

ACLX

Baird analyst Jack Allen maintains an Outperform rating on Arcellx (NASDAQ:ACLX) and raises the price target from $40 to $52.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:57 pm

LPTX

Baird analyst Joel Beatty has maintained an Outperform rating on Leap Therapeutics (NASDAQ:LPTX), but lowered the price target from $30 to $20.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:55 pm

TCON

Baird analyst Joel Beatty has maintained an Outperform rating on TRACON Pharma (NASDAQ:TCON) but lowered the price target from $7 to $3.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:54 pm

CAE

B of A Securities analyst Ronald Epstein maintains a Neutral rating on CAE (NYSE:CAE) and raises the price target from $33 to $37.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:52 pm

TSX:MATR

BMO Capital analyst John Gibson has upgraded Shawcor from Market Perform to Outperform and raised the price target from C$23 to C$26.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 12:51 pm

PHVS

Pharvaris shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $10 to $34.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:50 pm